William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on HROW stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors surrounding Harrow Health’s strategic acquisition and market positioning. The company recently secured exclusive U.S. commercial rights to two biosimilars, Byooviz and Opuviz, from Samsung Bioepis, which are alternatives to Lucentis and Eylea. This acquisition is expected to enhance Harrow’s revenue streams with minimal additional investment, leveraging their existing infrastructure in the retina market.
Furthermore, Harrow’s leadership team has significant experience in the anti-VEGF space, which is crucial for the successful commercialization of these biosimilars. Although the biosimilar market may not be the most glamorous, Harrow’s strategic positioning and experienced team make this a promising venture. The anticipated revenue recognition from Byooviz in 2026 and the expected launch of Opuviz in 2027 further solidify the company’s growth prospects, justifying the Buy rating.
In another report released today, Lake Street also maintained a Buy rating on the stock with a $42.00 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HROW in relation to earlier this year.